Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

ClinicalTrials.gov ID: NCT01074008

Public ClinicalTrials.gov record NCT01074008. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 10:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination With Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Study identification

NCT ID
NCT01074008
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Enrollment
74 participants

Conditions and interventions

Interventions

  • ABT-072 Drug
  • ABT-333 Drug
  • ABT-450 Drug
  • Peginterferon alpha-2a Drug
  • Placebo Other
  • Ribavirin Drug
  • Ritonavir Drug

Drug · Other

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2010
Primary completion
May 31, 2011
Completion
Dec 31, 2011
Last update posted
Jan 7, 2015

2010 – 2012

United States locations

U.S. sites
25
U.S. states
16
U.S. cities
22
Facility City State ZIP Site status
Site Reference ID/Investigator# 23392 Phoenix Arizona 85054
Site Reference ID/Investigator# 23370 Anaheim California 92801
Site Reference ID/Investigator# 23387 La Jolla California 92037
Site Reference ID/Investigator# 23388 Los Angeles California 90048
Site Reference ID/Investigator# 23371 Aurora Colorado 80045
Site Reference ID/Investigator# 23369 Orlando Florida 32803
Site Reference ID/Investigator# 26362 Orlando Florida 32809
Site Reference ID/Investigator# 23373 Chicago Illinois 60611
Site Reference ID/Investigator# 24908 Chicago Illinois 60612
Site Reference ID/Investigator# 23381 Indianapolis Indiana 46202-5121
Site Reference ID/Investigator# 23372 Baton Rouge Louisiana 70810
Site Reference ID/Investigator# 24710 New Orleans Louisiana 70112
Site Reference ID/Investigator# 23391 Baltimore Maryland 21287
Site Reference ID/Investigator# 23377 Detroit Michigan 48202
Site Reference ID/Investigator# 24909 Saint Paul Minnesota 55114
Site Reference ID/Investigator# 35842 New York New York 10016
Site Reference ID/Investigator# 23379 New York New York 10021
Site Reference ID/Investigator# 23375 Chapel Hill North Carolina 27599-7584
Site Reference ID/Investigator# 23385 Durham North Carolina 27705
Site Reference ID/Investigator# 23376 Dallas Texas 75203
Site Reference ID/Investigator# 24891 Houston Texas 77030
Site Reference ID/Investigator# 23382 San Antonio Texas 78215
Site Reference ID/Investigator# 24715 Salt Lake City Utah 84132-2410
Site Reference ID/Investigator# 25463 Seattle Washington 98101
Site Reference ID/Investigator# 23383 Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01074008, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 7, 2015 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01074008 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →